Work

Phase Ib study evaluating safety and pharmacokinetics (PK) of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate (LY) when combined with chemoradiotherapy in newly diagnosed malignant gliomas.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.2039

Authors: Cristina Suarez, Jordi Rodon, Annick Desjardins, Peter A. J. Forsyth, Ivelina Gueorguieva, Ann Cleverly, Tiana Burkholder, Durisala Desaiah, Michael M. F. Lahn, Wolfgang Wick

Institutions: Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Duke Medical Center, Moffitt Cancer Center, Eli Lilly (United Kingdom), Eli Lilly (United States), Heidelberg University, University Hospital Heidelberg

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2744130134

Cites:

Cited by: 6

Related to: 10